Deutsche Bank Upgrades Intercept Pharmaceuticals to Outperform (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities research analysts at Deutsche Bank to an “outperform” rating in a research note issued to investors on Tuesday. The firm currently has a $500.00 price target on the stock, up from their previous price target of $395.00. Deutsche Bank’s target price indicates a potential upside of 110.81% from the stock’s previous close.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 16.59% during mid-day trading on Tuesday, hitting $276.52. The stock had a trading volume of 6,088,050 shares. Intercept Pharmaceuticals has a 52-week low of $42.41 and a 52-week high of $497.00. The stock’s 50-day moving average is $232.6 and its 200-day moving average is $291.7. The company’s market cap is $5.831 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ICPT. Analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, June 30th. They set an “outperform” rating and a $425.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $503.00.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.